Hyphens Pharma (SGX:1J5) subsidiary Hyphens Pharma entered into a marketing and distribution agreement with medac Gesellschaft für klinische Spezialpräparate for the exclusive rights to register and commercialize Metoject(r) in Singapore, Malaysia, the Philippines, and Vietnam.
Metoject(r) is a subcutaneous autoinjector pen used for the treatment of rheumatoid arthritis, according to a filing with the Singapore Exchange on Tuesday.
The pen is already commercialized in over 15 states in Europe, the US and Japan.
Shares of Hyphens Pharma were up nearly 2% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。